I78-tfw_yef-dg_rt

About I78-tfw_yef-dg_rt

This author has not yet filled in any details.
So far I78-tfw_yef-dg_rt has created 16 blog entries.

OncoTartis has concluded a $6 million financing round to support the Phase 1 clinical trial of the lead drug candidate OT-82.

OncoTartis Closes $6M Financing Round. BUFFALO, N.Y., Dec. 11, 2017 /PRNewswire/ -- OncoTartis, Inc., a biotechnology company developing a novel category of anti-cancer drugs, has concluded a $6 million financing round to support the Phase 1 clinical trial of its lead drug candidate, OT-82.  Participants in the round included Norma Investments, representing businessman Roman Abramovich, and Pharmstandard International S.A., a venture arm of the largest Russian pharmaceutical company, based in Luxembourg. OT-82 has been isolated for its selective toxicity for a broad range of hematological malignancies. The drug candidate, a Nicotinamide phosphoribosyltransferase (NAMPT) inhibitor, has demonstrated high efficacy in a variety [...]

December 11th, 2017|

OT-82 shows impressive effectiveness in systemic patient-derived xenografts from pediatric resistant ALL patients

The Preclinical Testing Consortium (PPTC) is a US National Cancer Institute-funded initiative aimed at prioritizing effective drugs for clinical evaluation in pediatric cancers. OT-82 was selected for testing into this program. Results obtained with OT-82 showed impressive effectiveness in systemic patient-derived xenografts from pediatric resistant ALL patients. In addition, OT-82 demonstrated synergy with AraC in combination therapy. Consequently NAMPT inhibition by OT-82 is an attractive strategy for treating leukemia, and these data support further evaluation of this drug in the treatment of high-risk pediatric ALL.

June 2nd, 2017|

OncoTartis have successfully completed preclinical GLP Toxicology, Pharmacokinetics and Safety studies

OncoTartis have successfully completed preclinical GLP Toxicology, Pharmacokinetics and Safety studies demonstrating wide therapeutic window of OT-82. In the course of the studies, no ophthalmic toxicity in monkeys and mice was found. The drug did not show any cardiac toxicity in monkey either. Based on the results of pre-clinical studies as well as GLP studies, a dose range for Phase 1 clinical trials was calculated. This trial will open in the beginning of 2018 and first signs of efficacy are projected to be seen already in the first cohorts.

March 10th, 2017|

September 28, 2016: In-life phase of GLP Toxicology studies is completed.

September 28th, 2016|

Pharmatek, Inc., a San Diego based contract development & manufacturing company, started the development of OT-82 dosage form for human clinical studies.

August 1st, 2016|

Oncotartis raised $1.85 million in a Series B financing from its original investor – Bioprocess Capital Ventures. Proceeds will be used to complete all IND-enabling works and prepare for IND submission.

July 1st, 2016|

OncoTartis has initiated OT-82 GLP Toxicology and Safety Pharmacology studies at Pharmaron, Ltd., US FDA-inspected Clinical Research Organization.

June 27th, 2016|

Pediatric Preclinical Testing Consortium (PPTC) funded by the National Cancer Institute has selected drug candidate OT-82 to be tested in multiple xenograft models of pediatric ALL (Acute Lymphocytic Leukemia).

PPTC  is a multi-center consortium that is testing newly developed drugs against a broad range of childhood malignancies for acceleration into clinical trials.

March 15th, 2016|

Children’s Cancer Institute of Australia for Medical Research has become a shareholder of Oncotartis and one of its strategic research partners.

April 15th, 2015|

Oncotartis in collaboration with scientists from the Children’s Cancer Institute of Australia for Medical Research (CCIA) initiated testing of OT-82 in systemic preclinical models based on patient-derived cells from pediatric ALL patients with rearranged Mixed Lineage Leukemia gene.

March 30th, 2015|